🌕 Gate Square · Mid-Autumn Creator Incentive Program is Live!
Share trending topic posts, and split $5,000 in prizes! 🎁
👉 Check details & join: https://www.gate.com/campaigns/1953
💝 New users: Post for the first time and complete the interaction tasks to share $600 newcomer pool!
🔥 Today's Hot Topic: #MyTopAICoin#
Altcoins are heating up, AI tokens rising! #WLD# and #KAITO# lead the surge, with WLD up nearly 48% in a single day. AI, IO, VIRTUAL follow suit. Which potential AI coins are you eyeing? Share your investment insights!
💡 Post Ideas:
1️⃣ How do you see AI tokens evolving?
2️⃣ Wh
Global Real-World Study Results of the Largest-scale JAK1 Inhibitor Released
On March 8th, Jinshi Data reported that at the recent AAD meeting in the United States, the interim results of the world's largest JAK1 inhibitor, Abrocitinib, in the real world study AHEAD (Abrocitinib CHinese rEgistry on AD) were internationally released. This provides more real-world research and medical evidence data for the innovative small molecule drug with high selectivity JAK1 inhibitor in the field of atopic dermatitis (AD), further strengthening the clinical scientific basis to optimize treatment strategies and drive the reshaping of AD diagnosis and treatment pathways.